[HTML][HTML] Mesenchymal stem cells: current clinical progress in ARDS and COVID-19

K Xiao, F Hou, X Huang, B Li, ZR Qian, L Xie - Stem Cell Research & …, 2020 - Springer
Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate.
Survivors usually have low quality of life. Current clinical management strategies are …

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

H Qin, A Zhao - Protein & cell, 2020 - academic.oup.com
The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS …

Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential

E Gorman, J Millar, D McAuley… - Expert review of …, 2021 - Taylor & Francis
Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

W Qu, Z Wang, JM Hare, G Bu… - Stem Cells …, 2020 - academic.oup.com
Severe cases of COVID-19 infection, often leading to death, have been associated with
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …

[HTML][HTML] The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials

F Wang, Y Li, B Wang, J Li, Z Peng - Critical Care, 2023 - Springer
Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human
trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 …

Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential

M Khoury, PRM Rocco, DG Phinney, M Krampera… - Cytotherapy, 2020 - Elsevier
The serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic
have prompted a rapid global response to develop effective therapies that can lessen …

[HTML][HTML] Mesenchymal stem cells as a potential therapy for COVID-19

S Liu, D Peng, H Qiu, K Yang, Z Fu, L Zou - Stem cell research & therapy, 2020 - Springer
The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly
a major concern. The number of severe cases has increased dramatically worldwide, while …

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect

A Can, H Coskun - Stem Cells Translational Medicine, 2020 - academic.oup.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus
disease 2019 (COVID-19) pandemic has become a global health crisis with an extremely …

[HTML][HTML] Mesenchymal stem cell-based therapy as an alternative to the treatment of acute respiratory distress syndrome: current evidence and future perspectives

S Fernández-Francos, N Eiro… - International journal of …, 2021 - mdpi.com
Acute respiratory distress syndrome (ARDS) represents a current challenge for medicine
due to its incidence, morbidity and mortality and, also, the absence of an optimal treatment …

[HTML][HTML] Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure

N Durand, J Mallea, AC Zubair - NPJ Regenerative medicine, 2020 - nature.com
The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the
end of 2019 in Hubei province China, is now the cause of a global pandemic present in over …